$300,000.00 in Sales Expected for Galmed Pharmaceuticals (GLMD) This Quarter

Brokerages expect Galmed Pharmaceuticals (NASDAQ:GLMD) to post sales of $300,000.00 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Galmed Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $280,000.00 and the highest estimate coming in at $300,000.00. Galmed Pharmaceuticals posted sales of $270,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The firm is scheduled to announce its next earnings results on Monday, July 30th.

On average, analysts expect that Galmed Pharmaceuticals will report full year sales of $850,000.00 for the current financial year, with estimates ranging from $550,000.00 to $1.17 million. For the next financial year, analysts anticipate that the firm will post sales of $3.00 million per share. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Wednesday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,073.09% and a negative return on equity of 110.46%.

GLMD has been the subject of a number of research reports. ValuEngine cut shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Tuesday, May 15th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Finally, HC Wainwright raised their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, February 12th. Six research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $19.10.

Large investors have recently added to or reduced their stakes in the stock. 683 Capital Management LLC increased its position in Galmed Pharmaceuticals by 18.2% during the fourth quarter. 683 Capital Management LLC now owns 649,295 shares of the biopharmaceutical company’s stock worth $5,941,000 after acquiring an additional 100,000 shares during the period. Sphera Funds Management LTD. bought a new position in Galmed Pharmaceuticals in the 4th quarter valued at about $2,164,000. Renaissance Technologies LLC bought a new position in Galmed Pharmaceuticals in the 4th quarter valued at about $345,000. Meitav Dash Investments Ltd. bought a new position in Galmed Pharmaceuticals in the 4th quarter valued at about $4,357,000. Finally, Park West Asset Management LLC increased its holdings in Galmed Pharmaceuticals by 4.4% in the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after buying an additional 12,347 shares during the period. 17.28% of the stock is currently owned by institutional investors and hedge funds.

Shares of Galmed Pharmaceuticals traded down $0.18, reaching $7.33, during mid-day trading on Monday, according to Marketbeat.com. 77,800 shares of the company were exchanged, compared to its average volume of 68,492. The stock has a market cap of $115.46 million, a PE ratio of -7.48 and a beta of 2.73. Galmed Pharmaceuticals has a twelve month low of $3.61 and a twelve month high of $12.22.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply